ALS top target as US agencies link up

US agencies the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have announced the launch of the Critical Path for Rare Neurodegenerative Diseases (CP-RND).

This public-private partnership is aimed at advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases.

"The goal to finally produce a treatment that stops the tragic progression of ALS"The Critical Path InstituteExternal Link Disclaimer (C-Path) is the convener of the partnership, bringing together experts in rare neurodegenerative diseases, including, but not limited to, patient communities, advocacy organizations, and private entities.